Abelacimab, a factor XI inhibitor, demonstrated a 62–69% reduction in major bleeding compared to rivaroxaban in atrial fibrillation patients at moderate-to-high stroke risk, with comparable safety and ...

Subcutaneous injection of abelacimab results in lower levels of free factor XI and significantly fewer bleeding events than rivaroxaban in patients with atrial fibrillation at moderate-to-high risk ...